p62 participates in the inhibition of NF-κB signaling and apoptosis induced by sulfasalazine in human glioma U251 cells

Oncology Reports

Volumn 34, Issue 1, 2015, Pages 235-243

  Su, Jing ^a   Liu, Fei ^a   Xia, Meihui ^a   Xu, Ye ^b   Li, Xiaoning ^a   Kang, Jinsong ^a   Li, Yulin ^a   Sun, Liankun ^a  

^a JILIN UNIVERSITY   (China)

^b JILIN MEDICAL COLLEGE   (China)

Author keywords

Apoptosis; Autophagy; Nuclear factor B; p62 sequestosome 1; Sulfasalazine

Indexed keywords

3 METHYLADENINE; CELL PROTEIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LC3 PROTEIN; PROTEIN P62; SALAZOSULFAPYRIDINE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SQSTM1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; GLIOMA; HUMAN; HUMAN CELL; IC50; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; PATHOLOGY; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; GLIOMA; HUMANS; NF-KAPPA B; SIGNAL TRANSDUCTION; SULFASALAZINE;

EID: 84930027657     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3944     Document Type: Article

References (38)

1. Nagai S, Washiyama K, Kurimoto M, Takaku A, Endo S and Kumanishi T: Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma. J Neurosurg 96: 909-917, 2002.
2. Hayashi S, Yamamoto M, Ueno Y, Ikeda K, Ohshima K, Soma G and Fukushima T: Expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 and c-Myc in human astrocytomas. Neurol Med Chir (Tokyo) 41: 187-195, 2001.
3. 6-alkylating agents in human glioblastomas. J Clin Oncol 24: 274-287, 2006.
4. Lo M, Wang YZ and Gout PW: The x(c)-cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol 215: 593-602, 2008.
5. Ryan BM, Russel MG, Langholz E and Stockbrugger RW: Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. Am J Gastroenterol 98: 1682-1687, 2003.
6. Narang VS, Pauletti GM, Gout PW, Buckley DJ and Buckley AR: Suppression of cystine uptake by sulfasalazine inhibits proliferation of human mammary carcinoma cells. Anticancer Res 23: 4571-4579, 2003.
7. Gout PW, Simms CR and Robertson MC: In vitro studies on the lymphoma growth-inhibitory activity of sulfasalazine. Anticancer Drugs 14: 21-29, 2003.
8. Robe PA, Martin DH, Nguyen-Khac MT, Artesi M, Deprez M, Albert A, Vanbelle S, Califice S, Bredel M and Bours V: Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer 9: 372, 2009.
9. Robe PA, Bentires-Alj M, Bonif M, Rogister B, Deprez M, Haddada H, Khac MT, Jolois O, Erkmen K, Merville MP, et al: In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res 10: 5595-5603, 2004.
10. Habens F, Srinivasan N, Oakley F, Mann DA, Ganesan A and Packham G: Novel sulfasalazine analogues with enhanced NF-κB inhibitory and apoptosis promoting activity. Apoptosis 10: 481-491, 2005.
11. Müerköster S, Arlt A, Witt M, Gehrz A, Haye S, March C, Grohmann F, Wegehenkel K, Kalthoff H, Fölsch UR, et al: Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer 104: 469-476, 2003.
12. Ogier-Denis E and Codogno P: Autophagy: a barrier or an adaptive response to cancer. Biochim Biophys Acta 1603: 113-128, 2003.
13. Shintani T and Klionsky DJ: Autophagy in health and disease: a double-edged sword. Science 306: 990-995, 2004.
14. Marino G and Lopez-Otin C: Autophagy: molecular mechanisms, physiological functions and relevance in human pathology. Cell Mol Life Sci 61: 1439-1454, 2004.
15. Eskelinen EL: Maturation of autophagic vacuoles in mammalian cells. Autophagy 1: 1-10, 2005.
16. Djavaheri-Mergny M, Amelotti M, Mathieu J, Besançon F, Bauvy C, Souquère S, Pierron G and Codogno P: NF-kappaB activation represses tumor necrosis factor-alpha-induced autophagy. J Biol Chem 281: 30373-30382, 2006.
17. Trocoli A and Djavaheri-Mergny M: The complex interplay between autophagy and NF-kappaB signaling pathways in cancer cells. Am J Cancer Res 1: 629-649, 2011.
18. c-cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. Cancer Chemother Pharmacol 64: 463-472, 2009.
19. Yu H, Su J, Xu Y, Kang J, Li H, Zhang L, Yi H, Xiang X, Liu F and Sun L: p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins. Eur J Cancer 47: 1585-1594, 2011.
20. White E, Karp C, Strohecker AM, Guo Y and Mathew R: Role of autophagy in suppression of inflammation and cancer. Curr Opin Cell Biol 22: 212-217, 2010.
21. Rosenfeldt MT and Ryan KM: The multiple roles of autophagy in cancer. Carcinogenesis 32: 955-963, 2011.
22. Sanz L, Sanchez P, Lallena MJ, Diaz-Meco MT and Moscat J: The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation. EMBO J 18: 3044-3053, 1999.
23. Wooten MW, Seibenhener ML, Mamidipudi V, Diaz-Meco MT, Barker PA and Moscat J: The atypical protein kinase C-interacting protein p62 is a scaffold for NF-kappaB activation by nerve growth factor. J Biol Chem 276: 7709-7712, 2001.
24. Wooten MW, Geetha T, Seibenhener ML, Babu JR, Diaz-Meco MT and Moscat J: The p62 scaffold regulates nerve growth factor-induced NF-kappaB activation by influencing TRAF6 polyubiquitination. J Biol Chem 280: 35625-35629, 2005.
25. Moscat J, Diaz-Meco MT and Wooten MW: Signal integration and diversification through the p62 scaffold protein. Trends Biochem Sci 32: 95-100, 2007.
26. Moscat J, Diaz-Meco MT, Albert A and Campuzano S: Cell signaling and function organized by PB1 domain interactions. Mol Cell 23: 631-640, 2006.
27. Duran A, Linares JF, Galvez AS, Wikenheiser K, Flores JM, Diaz-Meco MT and Moscat J: The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell 13: 343-354, 2008.
28. Rolland P, Madjd Z, Durrant L, Ellis IO, Layfield R and Spendlove I: The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocr Relat Cancer 14: 73-80, 2007.
29. Su J, Xu Y, Zhou L, Yu HM, Kang JS, Liu N, Quan CS and Sun LK: Suppression of chloride channel 3 expression facilitates sensitivity of human glioma U251 cells to cisplatin through concomitant inhibition of Akt and autophagy. Anat Rec (Hoboken) 296: 595-603, 2013.
30. Liu N, Xu Y, Sun JT, Su J, Xiang XY, Yi HW, Zhang ZC and Sun LK: The BH3 mimetic S1 induces endoplasmic reticulum stress-associated apoptosis in cisplatin-resistant human ovarian cancer cells although it activates autophagy. Oncol Rep 30: 2677-2684, 2013.
31. Guo W, Zhao Y, Zhang Z, Tan N, Zhao F, Ge C, Liang L, Jia D, Chen T, Yao M, et al: Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma. Cancer Lett 312: 55-61, 2011.
32. Moscat J and Diaz-Meco MT: p62 at the crossroads of autophagy, apoptosis and cancer. Cell 137: 1001-1004, 2009.
33. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammationassociated cancer. Nature 431: 461-466, 2004.
34. Zanotto-Filho A, Braganhol E, Schröder R, De Souza LH, Dalmolin RJ, Pasquali MA, Gelain DP, Battastini AM and Moreira JC: NFkappaB inhibitors induce cell death in glioblastomas. Biochem Pharmacol 81: 412-424, 2011.
35. Kesanakurti D, Chetty C, Rajasekhar Maddirela D, Gujrati M and Rao JS: Essential role of cooperative NF-κB and Stat3 recruitment to ICAM-1 intronic consensus elements in the regulation of radiation-induced invasion and migration in glioma. Oncogene 32: 5144-5155, 2013.
36. Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY and Sontheimer H: Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci 25: 7101-7110, 2005.
37. Moriuchi S, Glorioso JC, Maruno M, Izumoto S, Wolfe D, Huang S, Cohen JB and Yoshimine T: Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant IkappaBalpha and HSV thymidine kinase. Cancer Gene Ther 12: 487-496, 2005.
38. Martin P, Diaz-Meco MT and Moscat J: The signaling adapter p62 is an important mediator of T helper 2 cell function and allergic airway inflammation. EMBO J 25: 3524-3533, 2006.